ClinicalTrials.gg
RecruitingNCT07212504NACC-ECUpdated Oct 28, 2025

Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory Problems

An interventional study of Active Brainsway H7-Coil Deep TMS System and Sham Brainsway H1-Coil Deep TMS System in Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD), sponsored by Rotman Research Institute at Baycrest. Recruiting at 1 site in Canada. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-10-28.

Sponsored by Rotman Research Institute at Baycrest · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 224 studies in Cognitive Dysfunction with a site in Canada — 61 open to participants now, 80 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.

Planned enrollment
120th of 171
30 · median 64
Started
2025
with 23 others
No phase
116 of 224
37 open now
Primary completion
2027-03
later than 44 of 79 live
Registered
213th of 224
by date

Among the 224 studies in Cognitive Dysfunction with a site in Canada, this one is the 120th largest by planned enrollment of the 171 interventional ones that give a count, is one of 24 that started in 2025, is one of 116 with no phase, reaches primary completion later than 44 of the 79 other live ones, and was the 213th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

61 of the 224 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:

55 more — sign in →

All 61 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 224 studies in Cognitive Dysfunction with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol in combination with cognitive training can improve cognitive abilities in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI). The study will look at whether it is safe and tolerable to use accelerated dTMS to enhance the benefits of cognitive training in older adults, and will also gather early information on the effects of accelerated dTMS on memory and other cognitive abilities.

Read the detailed description

This study will examine the effects of combining cognitive remediation with accelerated intermittent theta burst stimulation (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to target the anterior cingulate cortex (ACC) in older adults aged 55-85 with MCI or SCD. Thirty older adults will participate in a single site, double-blind, randomized sham-controlled trial using an accelerated schedule of multiple dTMS sessions per day for 2-5 consecutive days, followed by 6 weeks of online cognitive remediation for both sham and dTMS interventions. The primary goal of the study is to establish the feasibility of an a-iTBS protocol combined with cognitive training in older adults with Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD) and to obtain preliminary evidence of treatment efficacy.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Subjective Cognitive Decline (SCD)

Keywords

  • Mild Cognitive Impairment
  • Subjective Cognitive Decline
  • Transcranial Magnetic Stimulation (TMS)
  • Intermittent Theta Burst Stimulation
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 55 - 85 years of age (on the day of randomization)
  • are male or female
  • have a diagnosis of mild cognitive impairment (MCI) based on score \< 26 or where available, results from clinical neuropsychological assessment, OR subjective memory concerns and first degree relative, living or deceased, with a probable or confirmed diagnosis of AD
  • score 24 or higher on the Mini Mental State Examination (MMSE)
  • are willing to provide
  • are able to follow the treatment schedule
  • are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)
  • have a satisfactory safety screening questionnaire for TMS

Exclusion criteria

Exclusion Criteria:

  • have a metal plate in their head(such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe.
  • have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures
  • have a cardiac pacemaker
  • have an implanted medication pump
  • have a central venous line
  • have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia
  • have a history of substance abuse in the last 6 months
  • have a history of stroke or other brain lesions
  • have a personal history of epilepsy
  • have a family history of epilepsy
  • are a pregnant or breast-feeding woman
  • have a history of abnormal MRI of the brain
  • have untreated hypo- or hyper-thyroidism
  • have unstable medical condition(s)
  • have any other known to TMS
  • are on unstable doses of any psychotropic medication such as antidepressants, antipsychotic, mood stabilizers or memory enhancing medications
  • regularly use benzodiazepines or other hypnotics within 2 weeks of randomization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    20-40 sessions of iTBS dTMS and 6-weeks of online cognitive remediation

    Device: Active Brainsway H7-Coil Deep TMS System

  • Sham comparator
    20-40 sessions of sham stimulation and 6-weeks of online cognitive remediation

    Device: Sham Brainsway H1-Coil Deep TMS System

Interventions

  • DeviceActive Brainsway H7-Coil Deep TMS System

    Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 2-5 consecutive days.

  • DeviceSham Brainsway H1-Coil Deep TMS System

    In addition to the active H7-coil, a sham coil is included in the H1-coil helmet.The sham treatment will be administered using the H1-coil helmet 6-8 times a day for 2-5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Percentage of dTMS sessions attended by participants

    Time frame: 1 week

  2. Incidence and type of of adverse events experienced during treatment (participant-reported tolerability) based on the Adverse Events Questionnaire (AEQ)

    The AEQ asks about symptoms related immediately after TMS administration where patients rate symptom severity from 1 (absent) to 4 (severe) and whether they believe it is related to TMS from 1 (no) to 5 (definitely).

    Time frame: 9 weeks

  3. The number of participants who prematurely withdraw and reasons for withdrawal

    Time frame: 9 weeks

  4. Change from baseline memory scores on computerized neuropsychological battery following the final session on day 5

    Memory score from memory tests in the neuropsychological battery at baseline will be compared to after 5 days of TMS and after 6 weeks of cognitive training the active intervention group compared to the sham. A higher memory score indicates better memory performance. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size.

    Time frame: 9 weeks

  5. Change from baseline executive function scores on computerized neuropsychological battery following final session on day 5

    Executive function scores from tests on the neuropsychological battery will be compared from baseline to after days of dTMS and after 6 weeks of cognitive training in the active intervention group compared to sham. A higher score on these tests indicate greater executive functioning. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size.

    Time frame: 9 weeks

Secondary outcomes

  1. The change in baseline in scores on the Geriatric Anxiety Inventory (GAI) following 5 days of dTMS

    The GAI is a 20-item self-report measure of anxiety developed for older adults. Administration time is approximately 5 minutes. The GAI scores range from 0-20, with higher scores indicating more anxiety.

    Time frame: 1 week

  2. The change in resting state activity as measured with electroencephalography (EEG) following 5 days of dTMS

    Time frame: 1 week

  3. The change in slow wave activity in the posterior default mode network (posterior cingulate cortex) as measured with MEG following 5 days of dTMS

    Time frame: 1 week

  4. The change in functional connectivity within the default mode network based on Magnetic Resonance Imaging (MRI) following 5 days of dTMS

    Time frame: 1 week

  5. The change in baseline in scores on the Geriatric Depression Scale (GDS)

    GDS is a 15-item self-report scale that measures an elderly individual's mood. A score greater than 5 suggests that the individual may be depressed. Administration time is approximately 5 minutes. GDS scores range from 0-15 with a greater score indicating greater depressive symptoms.

    Time frame: 1 week

  6. The change in baseline slow wave as measured with electroencephalography (EEG) following 5 days of dTMS

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Mar 2027, 16 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 16 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Oct 8, 2025
StartEst.
Nov 15, 2025
Primary completionEst.
Mar 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Oct 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07212504
Lead sponsor
Rotman Research Institute at Baycrest
Responsible party
Linda Mah, MD (Clinician Scientist, Rotman Research Institute at Baycrest) — Principal investigator
First posted
Oct 8, 2025
Start date
Nov 15, 2025 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Oct 28, 2025

Study contacts

Amanda Chao, MPH
Contact
preventad@research.baycrest.org
416-785-2500 ext. 3434
Linda Mah, MD
Contact
preventad@research.baycrest.org
416-785-2500 ext. 3434
Linda Mah, MD
principal investigator · Baycrest Rotman Research Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion